Valuation: Epigenomics AG

Market Cap 965K 1.1M 890K 822K 1.56M 105M 1.59M 10.67M 4.15M 51.73M 4.14M 4.04M 179M P/E 2024
-0.29x
P/E 2025 -2.51x
Enterprise Value 11.93M 13.62M 11.01M 10.17M 19.3M 1.3B 19.65M 132M 51.38M 640M 51.16M 50.02M 2.21B EV / Sales 2024
-
EV / Sales 2025 490x
Free-Float
70.75%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Investor Relations Contact - -
Corporate Officer/Principal 55 2024-01-31
Director TitleAgeSince
Chairman 58 2023-02-28
Director/Board Member 55 2020-05-31
Director/Board Member 56 2024-02-04
Change 5-day change 1-year change 3-year change Capi.($)
-0.07%-4.44%+113.06%+136.69% 4.48B
-3.17%-6.01%+71.72%+233.77% 3.33B
-0.95%-2.17%-29.90%-41.82% 1.96B
-1.61%+2.88%+151.76%-40.88% 1.94B
-2.68%-3.33%+49.32%+173.04% 1.46B
-2.70%-7.69%+121.54%-52.71% 873M
-3.58%-4.88%-10.03%+45.39% 881M
-1.61%+2.53%-36.86%-17.99% 487M
-8.72%-18.82%-5.99% - 488M
Average -2.79%-2.68%+47.18%+54.44% 1.77B
Weighted average by Cap. -1.91%-2.57%+71.08%+95.26%

Financials

2024 2025
Net sales - 24K 27.4K 22.15K 20.46K 38.82K 2.62M 39.53K 266K 103K 1.29M 103K 101K 4.45M
Net income -3.35M -3.83M -3.09M -2.86M -5.42M -366M -5.52M -37.09M -14.43M -180M -14.37M -14.05M -622M -314K -358K -290K -268K -508K -34.28M -517K -3.47M -1.35M -16.84M -1.35M -1.32M -58.28M
Net Debt 10.46M 11.94M 9.65M 8.91M 16.91M 1.14B 17.22M 116M 45.02M 561M 44.83M 43.83M 1.94B 10.97M 12.52M 10.12M 9.35M 17.74M 1.2B 18.06M 121M 47.22M 588M 47.02M 45.98M 2.04B
Logo Epigenomics AG
Epigenomics AG is a Germany-based molecular diagnostics company focused on blood-based detection, prognosis and monitoring of cancers using deoxyribonucleic acid (DNA) methylation technology. It develops and commercializes blood-based diagnostic products across multiple cancer indications. The Company's main product is Epi proColon, a blood test for colorectal cancer screening. Along with the blood-based tests the Company offers services related to research, product development, regulatory approval and manufacturing of in-vitro diagnostic (IVD) products. It also offers Epi proLung, a blood-based test that detects the presence of lung cancer in blood plasma. The Company is present in Europe and the United States.
Employees
-